The most defensible summary is that tirzepatide is the evidence-complete option available today, and retatrutide is the higher-ceiling candidate whose full value and full risk profile will only be known when its phase 3 program is published, scrutinized, and, if warranted, translated into an approval and a label
I stopped taking it at that point and instead started using just one a month, which seemed like it gave me a small boost at high points in training
Trends Cancer 7 , 790804 (2021)
Love the ease of ordering, simple use and the product itself fabulous
Protective effects of intermittent hypoxia on brain and memory in a mouse model of apnea of prematurity
For a complete walkthrough with photos, check our peptide injection guide